<DOC>
	<DOCNO>NCT00195221</DOCNO>
	<brief_summary>Retrospective , multicenter study patient hemophilia B . This study place 20 50 hemophilia treatment center North America EU , design estimate frequency Class II III allergic reaction association administration FIX concentrate . Following informed consent eligibility , historical patient information include demographic , allergy history , hemophilia history , frequency severity allergic reaction ( ) , number exposure day product cause allergic reaction , exposure day blood product include FIX concentrate , treatment allergic reaction ( ) , outcome event ( ) , adverse event ( ) occur within 48 hour onset allergic reaction ( ) , rechallenge outcome , switch another FIX product ( applicable ) outcome , current status patient , result special study ( eg , skin RAST testing , alloantibody analysis , ect ) collect .</brief_summary>
	<brief_title>Study Describe Allergic Reactions Factor IX Patients With Hemophilia B</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<criteria>Written consent release patient information Living decease patient mild severe hemophilia B least 1 exposure replacement factor IX product ( ) . Living deceased patient first infusion FIX product 1 January 1991 31 December 2003 . There exclusion criterion .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Hemophilia B</keyword>
</DOC>